Page 83 - Immunization Practices News Today

CARSON CITY — As of Jan. 1, 2023, those with a Medicare drug coverage plan no longer have an out-of-pocket expense for vaccines recommended by the Advisory Committee on Immunization Practices (ACIP).

Use of the antibody treatment, the brand name for which is Beyfortus, still needs to be recommended by the ACIP.

This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year old in the United States every year.

Respiratory syncytial virus is the leading cause of hospitalization in American infants.

Sanofi's RSV antibody shot, nirsevimab, got FDA approval to protect infants on Monday.

The Food and Drug Administration (FDA) has approved a treatment for the prevention of RSV among infants and toddlers, making it the first preventive drug for the common virus that surged last winter among small children. The FDA approved nirsevimab-alip, or Beyfortus, for the prevention of respiratory syncytial virus (RSV) among newborns and infants born…

This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year old

(CNN) — This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization<a class="excerpt-read-more" href="https://whdh.com/news/fda-approves-antibody-to-protect-infants-from-rsv/">Read More</a>

This fall, parents and pediatricians will have a new option to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year old

The Food and Drug Administration on Monday approved an injectable drug that can protect children up to 2 years old from respiratory syncytial virus.